Baxter International (BAX -2.21%) probably didn’t want this trading week to end. According to data compiled by S&P Global Market Intelligence, the veteran medical device purveyor’s shares flew 19% higher over the period. That was hardly a surprise, as the company published a highly encouraging quarterly earnings report Thursday morning.
There’s nothing as good as a double beat
Baxter posted second-quarter sales of $2.96 billion, which was a 5% improvement over the same period of 2025. Of these, the company’s take in its native U.S. rose 4% to $1.6 billion, while international sales advanced 7% to $1.4 billion.
Image source: Getty Images.
Net income under generally accepted accounting practices (GAAP) rose more steeply, to $135 million from the year-ago profit of $122 million. On a per-share, non-GAAP (adjusted) basis, profitability fell 5% to $0.56 per share.
On average, analysts tracking Baxter stock were modeling $2.8 billion for revenue and $0.37 per share for adjusted net income.
In terms of product categories, both of Baxter’s revenue buckets saw sales increases. Medical products and therapies posted a 7% gain to nearly $2.1 billion, while healthcare systems and technologies rose 4% to $801 million.
Today’s Change
(-2.21%) $-0.59
Current Price
$26.16
Key Data Points
Market Cap
Day’s Range
$26.02 – $27.14
52wk Range
$15.73 – $30.00
Volume
9.3M
Avg Vol
6.9M
Gross Margin
32.05%
Dividend Yield
0.75%
Popping on guidance
Those tailwinds inspired Baxter management to raise its full-year guidance. It’s now anticipating sales growth of 3% to 4% over the 2025 tally. Previously, it was guiding for a flat-to-1% increase. Adjusted earnings per share (EPS) is projected to range from $1.95 to $2.15, up from the prior $1.85 to $2.05.
Baxter is solid, steady, and operating in a world where populations are getting proportionally older (and therefore requiring more medical care). It’s well-positioned for continued growth, and with that, its stock is more than worthy of consideration as a buy.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
